Literature DB >> 27803306

Both prolonged remission and Lupus Low Disease Activity State are associated with reduced damage accrual in systemic lupus erythematosus.

Michel W P Tsang-A-Sjoe1, Irene E M Bultink2, Maaike Heslinga2, Alexandre E Voskuyl2.   

Abstract

OBJECTIVES: To identify predictors of organ damage and specifically the relationship between prolonged disease remission or low disease activity and damage accrual in a longitudinal cohort of SLE patients.
METHODS: Data were prospectively assessed including the occurrence of minor/major flares. Once a year remission and Lupus Low Disease Activity State (LLDAS) were determined retrospectively. A prediction model for damage accrual during follow-up was constructed with backward logistic regression analyses. Secondly, odds ratios (ORs) for damage accrual (SLICC damage index increase of ⩾ 1 during follow-up) were calculated for patients with or without prolonged remission during 5 years, and with or without LLDAS in ⩾ 50% of observations.
RESULTS: Data from 183 patients with a median follow-up duration of 5.0 years were analysed. The most significant predictors for damage accrual were: occurrence of ⩾ 1 major flare, mean daily prednisone dose during follow-up and nephrological manifestations at baseline. Prolonged remission was present in 32.5% (38/117) and LLDAS in ⩾ 50% of observations in 64.5% (118/183) of patients. Both the presence of prolonged remission during 5 years and LLDAS in ⩾ 50% of observations were associated with a reduced risk of damage accrual (OR = 0.20, 95% CI: 0.07, 0.53, P = 0.001 and OR = 0.52, 95% CI: 0.28, 0.99, P = 0.046, respectively).
CONCLUSION: This cohort study shows that prolonged remission and LLDAS were associated with an improved outcome, as determined by yearly assessments. In order to improve the outcome in SLE patients, future studies should investigate whether these targets can be reached actively with therapeutic strategies.
© The Author 2016. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  cohort study; damage accrual; flare; glucocorticoids; low disease activity; lupus low disease activity state; lupus nephritis; remission; systemic lupus erythematosus

Mesh:

Substances:

Year:  2016        PMID: 27803306     DOI: 10.1093/rheumatology/kew377

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  25 in total

1.  Predictors of predominant Lupus Low Disease Activity State (LLDAS-50).

Authors:  H Babaoglu; J Li; D Goldman; L S Magder; M Petri
Journal:  Lupus       Date:  2019-11-06       Impact factor: 2.911

Review 2.  [State of the art: systemic lupus erythematosus].

Authors:  J Mucke; R Fischer-Betz; M Schneider
Journal:  Z Rheumatol       Date:  2019-08       Impact factor: 1.372

3.  Comparison of Remission and Lupus Low Disease Activity State in Damage Prevention in a United States Systemic Lupus Erythematosus Cohort.

Authors:  Michelle Petri; Laurence S Magder
Journal:  Arthritis Rheumatol       Date:  2018-11       Impact factor: 10.995

4.  Factors associated with remission in patients with systemic lupus erythematosus: new insights into a desirable state.

Authors:  Jorge Romo-Tena; Roberto Reyna-de la Garza; Isaac Bartnicki-Navarrete; Jorge Alcocer-Varela; Diana Gómez-Martin
Journal:  Clin Rheumatol       Date:  2018-07-28       Impact factor: 2.980

Review 5.  2022 Systemic lupus erythematosus remission in clinical practice. Message for Polish rheumatologists.

Authors:  Katarzyna Pawlak-Buś; Piotr Leszczyński
Journal:  Reumatologia       Date:  2022-05-18

6.  Long-Term Clinical Outcome in Systemic Lupus Erythematosus Patients Followed for More Than 20 Years: The Milan Systemic Lupus Erythematosus Consortium (SMiLE) Cohort.

Authors:  Maria Gerosa; Lorenzo Beretta; Giuseppe Alvise Ramirez; Enrica Bozzolo; Martina Cornalba; Chiara Bellocchi; Lorenza Maria Argolini; Luca Moroni; Nicola Farina; Giulia Segatto; Lorenzo Dagna; Roberto Caporali
Journal:  J Clin Med       Date:  2022-06-22       Impact factor: 4.964

7.  Time to Lupus Low Disease Activity State in the Hopkins Lupus Cohort: Role of African American Ethnicity.

Authors:  Hakan Babaoğlu; Jessica Li; Daniel Goldman; Laurence S Magder; Michelle Petri
Journal:  Arthritis Care Res (Hoboken)       Date:  2020-01-09       Impact factor: 4.794

8.  Failure to achieve lupus low disease activity state (LLDAS) six months after diagnosis is associated with early damage accrual in Caucasian patients with systemic lupus erythematosus.

Authors:  Matteo Piga; Alberto Floris; Giulia Cappellazzo; Elisabetta Chessa; Mattia Congia; Alessandro Mathieu; Alberto Cauli
Journal:  Arthritis Res Ther       Date:  2017-11-10       Impact factor: 5.156

9.  Remission and low disease activity in systemic lupus erythematosus: an achievable goal even with fewer steroids? Real-life data from a monocentric cohort.

Authors:  Chiara Tani; Roberta Vagelli; Chiara Stagnaro; Linda Carli; Marta Mosca
Journal:  Lupus Sci Med       Date:  2018-02-27

10.  Lupus Low Disease Activity State (LLDAS) attainment discriminates responders in a systemic lupus erythematosus trial: post-hoc analysis of the Phase IIb MUSE trial of anifrolumab.

Authors:  Eric F Morand; Teodora Trasieva; Anna Berglind; Gabor G Illei; Raj Tummala
Journal:  Ann Rheum Dis       Date:  2018-02-02       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.